By ARUNAVA DAS in Kolkata, India, and XU WEIWEI in Hong Kong |
China Daily |
The tariffs proposed by the United States on generic medicines, featuring a 200 percent duty by 2029, not only represent a medium-term risk to India's $9.7 billion pharmaceutical export market but also hurt US patients, analysts said.
They added that Indian pharmaceutical companies can take the challenge as an opportunity to diversify their export destinations and innovate.
US President Donald Trump announced a phased tariff schedule for imported generic drugs: zero duty until August 2028, followed by 100 percent for one year, and 200 percent thereafter. He said in a social media post that the US aimed to push generic drugmakers to move production onshore.
